Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of ARGX-117 in adults with multifocal motor neuropathy
2023-507052-69-00Phase 2Authorised
- Sponsor
- argenx
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 2, open-label, single-arm trial of empasiprubart in multifocal motor neuropathy (MMN), sponsored by argenx. Primary endpoint: Safety outcomes. Planned start Mar 2023; status: authorised.
02
Drugs
empasiprubart
03
Conditions
multifocal motor neuropathy (MMN)
Beyond the preview
Go deeper on 2023-507052-69-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507052-69-00.